Grifols sa investor relations

Financial informationarticle_10154_10192_35215_1.
Shares and share capitalarticle_10154_10192_15134_2.
Barcelona on June the 1 article_10154_10192_32802_6.

Grifols has been working in the fields of transfusion, blood banking, protein therapeutics and laboratory analysis for more than 70 years.
Grifols and Talecris Announce Signing of Consent Agreement with FTC Staff.

For more information and the appropriate transparency forms, please contact TiGenix Investor Relations or the FSMA.
Kedrion announces that, effective 1st July, 2013, Grifols S.
Contact Investor Relationsmailto:investor.
Options are not suitable for all investors.
SA in TiGenix. Gri-Cel is a fully-owned subsidiary of Grifols, a world leader in plasma-derived therapeutics.
We are delighted to welcome CIC as a long-term investor in Morgan Stanley, and believe it is an important step in increasing the flow of capital between our countries and across these increasingly critical markets.
He has also served as finance director of Grifols S.
Biogen Idec and Grifols, among others, exemplify the idea that biotech firms and drugmakers can join forces and broaden their global reach in an ever-increasing populationwhile also serving the needs of their shareholders.
BRF SA (ADR) (NYSE:BRFS), Copa Holdings SA (NYSE:CPA .
Avinguda de la Generalitat, 152Parque empresarial Can Sant Joan Sant Cugat del VallesSpainPhone: 34 93 5712200Fax: 34-93-5710267www.